Equities analysts expect that Omeros Co. (NASDAQ:OMER) will post earnings per share of ($0.62) for the current quarter, Zacks Investment Research reports. Two analysts have made estimates for Omeros’ earnings, with estimates ranging from ($0.64) to ($0.59). Omeros reported earnings of ($0.23) per share during the same quarter last year, which indicates a negative year over year growth rate of 169.6%. The business is expected to announce its next quarterly earnings results on Tuesday, August 14th.
On average, analysts expect that Omeros will report full year earnings of ($2.39) per share for the current financial year, with EPS estimates ranging from ($2.55) to ($2.22). For the next year, analysts anticipate that the business will post earnings of ($0.85) per share, with EPS estimates ranging from ($1.91) to $0.21. Zacks’ EPS calculations are an average based on a survey of research firms that cover Omeros.
Omeros (NASDAQ:OMER) last posted its quarterly earnings results on Thursday, May 10th. The biopharmaceutical company reported ($0.62) EPS for the quarter, missing analysts’ consensus estimates of ($0.57) by ($0.05). The company had revenue of $1.59 million during the quarter, compared to analyst estimates of $2.08 million. During the same period in the prior year, the firm earned ($0.34) EPS. The business’s revenue for the quarter was down 87.0% compared to the same quarter last year.
A number of research firms recently commented on OMER. Zacks Investment Research upgraded Omeros from a “sell” rating to a “hold” rating in a report on Wednesday. ValuEngine downgraded shares of Omeros from a “buy” rating to a “hold” rating in a research report on Wednesday. HC Wainwright set a $34.00 price objective on shares of Omeros and gave the stock a “buy” rating in a research report on Thursday, May 3rd. BidaskClub upgraded shares of Omeros from a “sell” rating to a “hold” rating in a research report on Wednesday, May 9th. Finally, Maxim Group set a $25.00 price objective on shares of Omeros and gave the stock a “buy” rating in a research report on Sunday, May 13th. Seven research analysts have rated the stock with a hold rating and three have issued a buy rating to the stock. Omeros presently has an average rating of “Hold” and a consensus price target of $26.00.
In other Omeros news, VP Michael A. Jacobsen sold 23,792 shares of the firm’s stock in a transaction that occurred on Tuesday, May 15th. The shares were sold at an average price of $23.80, for a total transaction of $566,249.60. Following the completion of the sale, the vice president now directly owns 19,480 shares in the company, valued at $463,624. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Company insiders own 12.10% of the company’s stock.
Hedge funds have recently modified their holdings of the business. Wedbush Securities Inc. lifted its position in Omeros by 32.4% during the fourth quarter. Wedbush Securities Inc. now owns 94,923 shares of the biopharmaceutical company’s stock worth $1,844,000 after acquiring an additional 23,241 shares during the last quarter. Wells Fargo & Company MN raised its position in shares of Omeros by 73.4% in the fourth quarter. Wells Fargo & Company MN now owns 73,059 shares of the biopharmaceutical company’s stock valued at $1,419,000 after buying an additional 30,915 shares in the last quarter. Baird Financial Group Inc. raised its position in shares of Omeros by 9.0% in the fourth quarter. Baird Financial Group Inc. now owns 62,296 shares of the biopharmaceutical company’s stock valued at $1,210,000 after buying an additional 5,151 shares in the last quarter. State of Wisconsin Investment Board raised its position in shares of Omeros by 93.9% in the fourth quarter. State of Wisconsin Investment Board now owns 44,600 shares of the biopharmaceutical company’s stock valued at $867,000 after buying an additional 21,600 shares in the last quarter. Finally, Capital Analysts LLC raised its position in shares of Omeros by 885.6% in the fourth quarter. Capital Analysts LLC now owns 590,849 shares of the biopharmaceutical company’s stock valued at $36,125,000 after buying an additional 530,899 shares in the last quarter. Hedge funds and other institutional investors own 46.09% of the company’s stock.
Omeros stock traded up $0.29 during midday trading on Friday, reaching $19.69. 476,466 shares of the company’s stock were exchanged, compared to its average volume of 1,247,520. Omeros has a 52 week low of $8.36 and a 52 week high of $27.09. The company has a debt-to-equity ratio of -2.91, a quick ratio of 3.18 and a current ratio of 3.19. The stock has a market capitalization of $893.90 million, a P/E ratio of -24.92 and a beta of 3.63.
Omeros Company Profile
Omeros Corporation, a biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting inflammation, coagulopathies, and disorders of the central nervous system. The company markets OMIDRIA for use in cataract surgery or intraocular lens replacement in the United States.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Omeros Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Omeros and related companies with MarketBeat.com's FREE daily email newsletter.